(Q36162348)

12 August 2017

1 reference

title

Role of linezolid in the treatment of orthopedic infections (English)

1 reference

12 August 2017

1 reference

1

Matteo Bassetti

1 reference

12 August 2017

Elda Righi

2

1 reference

12 August 2017

Antonio Di Biagio

3

1 reference

12 August 2017

Raffaella Rosso

4

1 reference

12 August 2017

Andrea Beltrame

5

1 reference

12 August 2017

Dante Bassetti

6

1 reference

12 August 2017

1 June 2005

1 reference

Expert Review of Anti-infective Therapy

12 August 2017

1 reference

12 August 2017

3

1 reference

12 August 2017

3

1 reference

12 August 2017

343-352

1 reference

Bacteraemia and antibiotic resistance of its pathogens reported in England and Wales between 1990 and 1998: trend analysis

12 August 2017

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.3.343

In vitro activities of 28 antimicrobial agents against Staphylococcus aureus isolates from tertiary-care hospitals in Korea: a nationwide survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.3.343

The status of antimicrobial resistance in Taiwan among Gram-positive pathogens: the Taiwan Surveillance of Antimicrobial Resistance (TSAR) programme, 2000.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.3.343

Distribution of multi-resistant Gram-negative versus Gram-positive bacteria in the hospital inanimate environment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.3.343

Computer keyboards and faucet handles as reservoirs of nosocomial pathogens in the intensive care unit

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.3.343

Clinical trial results with linezolid, an oxazolidinone, in the treatment of soft tissue and postoperative gram-positive infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.3.343

Susceptibility of gram-positive cocci from 25 UK hospitals to antimicrobial agents including linezolid. The Linezolid Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.3.343

Risk of methicillin-resistant Staphylococcus aureus infection after previous infection or colonization

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.3.343

Antimicrobial resistance trends and outbreak frequency in United States hospitals

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.3.343

Oxazolidinones: activity, mode of action, and mechanism of resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.3.343

Role of rifampin for treatment of orthopedic implant-related staphylococcal infections: a randomized controlled trial. Foreign-Body Infection (FBI) Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.3.343

Antimicrobial Treatment of Orthopedic Implant-related Infections with Rifampin Combinations

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.3.343

Linezolid: a review of its use in the management of serious gram-positive infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.3.343

Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.3.343

Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.3.343

Randomized comparison of linezolid (PNU-100766) versus oxacillin-dicloxacillin for treatment of complicated skin and soft tissue infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.3.343

Pharmacokinetic and pharmacodynamic profile of linezolid in healthy volunteers and patients with Gram-positive infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.3.343

Quinupristin-dalfopristin and linezolid: evidence and opinion

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.3.343

Clinical relevance of bacteriostatic versus bactericidal mechanisms of action in the treatment of Gram-positive bacterial infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.3.343

Linezolid: pharmacokinetic characteristics and clinical studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.3.343

Linezolid: pharmacokinetic and pharmacodynamic evaluation of coadministration with pseudoephedrine HCl, phenylpropanolamine HCl, and dextromethorpan HBr.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.3.343

A pharmacokinetic evaluation of concomitant administration of linezolid and aztreonam

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.3.343

Linezolid absolute bioavailability and the effect of food on oral bioavailability

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.3.343

Pharmacokinetics and tissue penetration of linezolid following multiple oral doses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.3.343

Penetration of linezolid into bone, fat, muscle and haematoma of patients undergoing routine hip replacement

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.3.343

Linezolid penetration into osteo-articular tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.3.343

Linezolid penetration into bone and joint tissues infected with methicillin-resistant staphylococci

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.3.343

Efficacy of linezolid versus comparator therapies in Gram-positive infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.3.343

In vitro bactericidal activities of linezolid in combination with vancomycin, gentamicin, ciprofloxacin, fusidic acid, and rifampin against Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.3.343

In vitro activity of linezolid, synercid and telithromycin against genetically defined high level fluoroquinolone-resistant methicillin-resistant Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.3.343

In vitro activity of linezolid against multiply resistant Gram-positive clinical isolates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.3.343

Linezolid resistance in a clinical isolate of Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.3.343

Emergence of linezolid-resistant Enterococcus faecium during treatment of enterococcal infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.3.343

Linezolid-resistant Enterococcus faecalis isolated from a cord blood transplant recipient

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.3.343

Linezolid resistance since 2001: SENTRY Antimicrobial Surveillance Program

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.3.343

Resistance to linezolid. Are we surprised? How hard should we look?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.3.343

Linezolid resistance in Staphylococcus aureus: characterization and stability of resistant phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.3.343

A consensus statement on empiric therapy for suspected gram-positive infections in surgical patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.3.343

Worldwide assessment of linezolid's clinical safety and tolerability: comparator-controlled phase III studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.3.343

The efficacy and safety of linezolid as treatment for Staphylococcus aureus infections in compassionate use patients who are intolerant of, or who have failed to respond to, vancomycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.3.343

Comparative activity of linezolid and other new agents against methicillin-resistant Staphylococcus aureus and teicoplanin-intermediate coagulase-negative staphylococci

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.3.343

Linezolid for the treatment of multidrug-resistant, gram-positive infections: experience from a compassionate-use program

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.3.343

Linezolid versus teicoplanin in the treatment of Gram-positive infections in the critically ill: a randomized, double-blind, multicentre study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.3.343

Prospective, randomized study comparing quinupristin-dalfopristin with linezolid in the treatment of vancomycin-resistant Enterococcus faecium infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.3.343

Safety and tolerability of linezolid in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.3.343

Mechanisms for linezolid-induced anemia and thrombocytopenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.3.343

Linezolid and reversible myelosuppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.3.343

Challenges with linezolid therapy and reversible pancytopenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.3.343

Linezolid does not increase the risk of thrombocytopenia in patients with nosocomial pneumonia: comparative analysis of linezolid and vancomycin use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.3.343

Myelosuppression and serotonin syndrome associated with concurrent use of linezolid and selective serotonin reuptake inhibitors in bone marrow transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.3.343

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.3.343

Risk factors for anaemia in patients on prolonged linezolid therapy for chronic osteomyelitis: a case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.3.343

Hematologic effects of linezolid versus vancomycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.3.343

Resumption of linezolid therapy after myelotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.3.343

Linezolid and Serotonin Toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.3.343

Serotonin Syndrome after Concomitant Treatment with Linezolid and Citalopram

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.3.343

Linezolid in the treatment of osteomyelitis: results of compassionate use experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.3.343

Linezolid-associated toxic optic neuropathy: a report of 2 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.3.343

Peripheral neuropathy associated with prolonged use of linezolid

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.3.343

Linezolid-induced lactic acidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.3.343

Linezolid-induced bradycardia: a case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.3.343

Cost-minimization analysis and audit of antibiotic management of bone and joint infections with ambulatory teicoplanin, in-patient care or outpatient oral linezolid therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.3.343

An economic evaluation of a European cohort from a multinational trial of linezolid versus teicoplanin in serious Gram-positive bacterial infections: the importance of treatment setting in evaluating treatment effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.3.343

Economic evaluation of linezolid, flucloxacillin and vancomycin in the empirical treatment of cellulitis in UK hospitals: a decision analytical model

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.3.343

Economic impact and formulary positioning of linezolid: a new anti-Gram-positive antimicrobial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.3.343

Linezolid treatment for osteomyelitis due to vancomycin-resistant Enterococcus faecium

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.3.343

Linezolid treatment of prosthetic hip Infections due to methicillin-resistant Staphylococcus aureus (MRSA).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.3.343

Linezolid treatment of total prosthetic knee infection due to methicillin-resistant Staphylococcus epidermidis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.3.343

Successful treatment of vertebral osteomyelitis with linezolid in a patient receiving hemodialysis and with persistent methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus bacteremias.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.3.343

Clinical experience with linezolid in conjunction with wound coverage techniques for skin and soft-tissue infections and postoperative osteomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.3.343

Linezolid therapy of Staphylococcus aureus experimental osteomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.3.343

Role of oral antimicrobial therapy in the management of osteomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.3.343

Trends in the treatment of orthopaedic prosthetic infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.3.343

Prolonged suppressive antibiotic therapy for infected orthopedic prostheses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.3.343

Linezolid in the treatment of Gram-positive prosthetic joint infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.3.343

Treating foot infections in diabetic patients: a randomized, multicenter, open-label trial of linezolid versus ampicillin-sulbactam/amoxicillin-clavulanate

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.3.343

21 January 2018

Identifiers

DOI

10.1586/14787210.3.3.343

1 reference

12 August 2017

1 reference